- Joined
- Apr 4, 2015
- Messages
- 23,117
- Reaction score
- 17,865
- Points
- 113
I wondered out of all the supplements, research, nootropics; and other aminos; “ WHY WERE THEY MESSING WITH NAC(N-Acetyl L-Cysteine) a non-essential amino acid to try and BAN or make it hard to get !??? Well, after looking at the multiple companies and combinations they have been studying and investing in; Here is what I found: (quite remarkable)
Companies past/present/merged :
IntelGenx Technologies Corp., GABA Therapeutics, Ltd, Viridia Life Sciences, Inc., IntroSpect Digital Therapeutics, Inc., EmpathBio, Inc. and Revixia Life Sciences, Inc., and our controlled variable interest entities, Perception Neuroscience Holdings, Inc., Kures Inc., EntheogeniX Biosciences, Inc., Psyber Inc., Neuronasal, Inc., PsyProtix, Inc., InnarisBio, Inc., DemeRx IB, Inc. and Recognify Life Sciences, Inc.
REASON NAC WAS BEING TAKEN OFF MARKET :
Neuronasal: NN-101 for mTBI(Mild traumatic brain injury)
NN-101 is a novel intranasal formulation of N-acetylcysteine, or NAC. NAC is believed to stimulate the synthesis of glutathione, or GSH, an endogenous antioxidant that plays a protective role in the pathogenesis of mild traumatic brain injury, or mTBI. An orally administered formulation of NAC was shown to increase the probability of mTBI symptom resolution at seven days in a third-party study conducted by the U.S. Army. Neuronasal has also completed a pilot study of NN-101 in ten healthy volunteers. In this pilot study, NN-101 was observed to be {approximately 20 times and 100 times more brain-penetrant compared to intravenous, or IV, and oral NAC} respectively, and was well tolerated.
One of many Links if you would like to read the latest on NAC formulations/tests/etc : https://www.frontiersin.org/articles/10.3389/fnins.2021.635483/full
NAC nasal formulations , highly bioavailable Gluthianone seem to have some incredible effects for many afflictions.
Max

IntelGenx Technologies Corp., GABA Therapeutics, Ltd, Viridia Life Sciences, Inc., IntroSpect Digital Therapeutics, Inc., EmpathBio, Inc. and Revixia Life Sciences, Inc., and our controlled variable interest entities, Perception Neuroscience Holdings, Inc., Kures Inc., EntheogeniX Biosciences, Inc., Psyber Inc., Neuronasal, Inc., PsyProtix, Inc., InnarisBio, Inc., DemeRx IB, Inc. and Recognify Life Sciences, Inc.

Neuronasal: NN-101 for mTBI(Mild traumatic brain injury)
NN-101 is a novel intranasal formulation of N-acetylcysteine, or NAC. NAC is believed to stimulate the synthesis of glutathione, or GSH, an endogenous antioxidant that plays a protective role in the pathogenesis of mild traumatic brain injury, or mTBI. An orally administered formulation of NAC was shown to increase the probability of mTBI symptom resolution at seven days in a third-party study conducted by the U.S. Army. Neuronasal has also completed a pilot study of NN-101 in ten healthy volunteers. In this pilot study, NN-101 was observed to be {approximately 20 times and 100 times more brain-penetrant compared to intravenous, or IV, and oral NAC} respectively, and was well tolerated.
One of many Links if you would like to read the latest on NAC formulations/tests/etc : https://www.frontiersin.org/articles/10.3389/fnins.2021.635483/full
NAC nasal formulations , highly bioavailable Gluthianone seem to have some incredible effects for many afflictions.
Max